MicroRNA-429 Modulates Hepatocellular Carcinoma Prognosis and Tumorigenesis

Abstract EN

MicroRNA-429 (miR-429) may modify the development and progression of cancers; however, the role of this microRNA in the hepatocellular carcinoma (HCC) has not been well elaborated.

Here, we tested miR-429 expression in 138 pathology-diagnosed HCC cases and SMMC-7721 cells.

We found that miR-429 was upregulated in HCC tumor tissues and that the high expression of miR-429 was significantly correlated with larger tumor size (odd ratio (OR), 2.70; 95% confidence interval (CI), 1.28–5.56) and higher aflatoxin B1-DNA adducts (OR = 3.13, 95% CI = 1.47–6.67).

Furthermore, this microRNA overexpression modified the recurrence-free survival and overall survival of HCC patients.

Functionally, miR-429 overexpression progressed tumor cells proliferation and inhibited cell apoptosis.

These results indicate for the first time that miR-429 may modify HCC prognosis and tumorigenesis and may be a potential tumor therapeutic target.